ProAssurance (NYSE:PRA) Now Covered by StockNews.com

Investment analysts at StockNews.com began coverage on shares of ProAssurance (NYSE:PRA - Get Free Report) in a research note issued on Friday. The firm set a "hold" rating on the insurance provider's stock.

Several other equities research analysts also recently commented on the stock. Raymond James downgraded shares of ProAssurance from a "market perform" rating to an "underperform" rating in a research note on Thursday, April 10th. Citigroup lowered shares of ProAssurance to a "market perform" rating in a report on Thursday, April 3rd. Finally, Citizens Jmp cut ProAssurance from an "outperform" rating to a "market perform" rating in a report on Thursday, April 3rd. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating and one has assigned a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Hold" and an average price target of $18.67.

ProAssurance Price Performance

Shares of NYSE:PRA traded down $0.06 during midday trading on Friday, reaching $23.20. 381,885 shares of the company's stock were exchanged, compared to its average volume of 425,753. The firm has a market capitalization of $1.19 billion, a PE ratio of 27.95 and a beta of -0.09. The company's 50 day simple moving average is $20.23 and its two-hundred day simple moving average is $17.25. ProAssurance has a 12 month low of $10.76 and a 12 month high of $23.70. The company has a debt-to-equity ratio of 0.35, a quick ratio of 0.28 and a current ratio of 0.28.

ProAssurance (NYSE:PRA - Get Free Report) last released its quarterly earnings data on Monday, February 24th. The insurance provider reported $0.36 earnings per share for the quarter, beating analysts' consensus estimates of $0.17 by $0.19. The company had revenue of $287.52 million for the quarter, compared to the consensus estimate of $274.56 million. ProAssurance had a return on equity of 2.65% and a net margin of 3.71%. Equities research analysts expect that ProAssurance will post 0.8 earnings per share for the current fiscal year.

Hedge Funds Weigh In On ProAssurance

Several hedge funds have recently added to or reduced their stakes in the company. Mariner LLC lifted its position in ProAssurance by 4.2% during the 4th quarter. Mariner LLC now owns 17,007 shares of the insurance provider's stock valued at $271,000 after purchasing an additional 688 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in ProAssurance by 4.0% in the fourth quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 28,991 shares of the insurance provider's stock valued at $461,000 after buying an additional 1,127 shares during the period. Rhumbline Advisers lifted its holdings in ProAssurance by 0.8% in the fourth quarter. Rhumbline Advisers now owns 160,707 shares of the insurance provider's stock valued at $2,557,000 after buying an additional 1,281 shares during the period. Sterling Capital Management LLC grew its holdings in ProAssurance by 859.4% during the 4th quarter. Sterling Capital Management LLC now owns 1,631 shares of the insurance provider's stock worth $26,000 after acquiring an additional 1,461 shares during the period. Finally, GAMMA Investing LLC raised its position in shares of ProAssurance by 307.3% during the 1st quarter. GAMMA Investing LLC now owns 2,073 shares of the insurance provider's stock valued at $48,000 after acquiring an additional 1,564 shares during the last quarter. Institutional investors own 85.58% of the company's stock.

ProAssurance Company Profile

ProAssurance Corporation, through its subsidiaries, provides property and casualty insurance, and reinsurance products in the United States. The company operates through Specialty Property and Casualty, Workers' Compensation Insurance, and Segregated Portfolio Cell Reinsurance segments. It offers professional liability insurance to healthcare providers and institutions, and attorneys and their firms; medical technology liability insurance to medical technology and life sciences companies; and custom alternative risk solutions, including assumed reinsurance, loss portfolio transfers, and captive cell programs for healthcare professional liability insureds.